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Abstract
Objective: The aim of this study was to evaluate if urinary sediment cells
offered a robust alternative to muscle biopsy for the diagnosis of single mtDNA
deletions. Methods: Eleven adult patients with progressive external ophthalmo-
plegia and a known single mtDNA deletion were investigated. Urinary sediment
cells were used to isolate DNA, which was then subjected to long-range poly-
merase chain reaction. Where available, the patient‘s muscle DNA was studied
in parallel. Breakpoint and thus deletion size were identified using both Sanger
sequencing and next generation sequencing. The level of heteroplasmy was
determined using quantitative polymerase chain reaction. Results: We identified
the deletion in urine in 9 of 11 cases giving a sensitivity of 80%. Breakpoints
and deletion size were readily detectable in DNA extracted from urine. Mean
heteroplasmy level in urine was 38%  26 (range 8 - 84%), and 57%  28
(range 12 – 94%) in muscle. While the heteroplasmy level in urinary sediment
cells differed from that in muscle, we did find a statistically significant correla-
tion between these two levels (R = 0.714, P = 0.031(Pearson correlation)).
Interpretation: Our findings suggest that urine can be used to screen patients
suspected clinically of having a single mtDNA deletion. Based on our data, the
use of urine could considerably reduce the need for muscle biopsy in this
patient group.
Introduction
In humans, mitochondria are the only extra-nuclear orga-
nelles that have their own DNA; mitochondrial DNA
(mtDNA). This 16.5 kb circular genome encodes 13 pro-
teins that are subunits of respiratory chain complexes: the
remaining protein subunits are encoded by genes within
the nucleus. In addition to 13 proteins, the mtDNA
encodes 22 tRNA and 2 rRNA that participate in mito-
chondrial translation. Multiple copies of mtDNA are pre-
sent within each cell and a mutation in mitochondrial
genome can therefore, affect some or all of the copies;
coexistence of mutated and wild-type mtDNA is known
as heteroplasmy.
The first pathogenic mutations in mtDNA giving rise
to human disease, were identified in 1988, and were single
large-scale mitochondrial deletions (single deletions).1
Subsequently more than 150 single-nucleotide changes
and rearrangements have been identified.2
Single deletions contribute to ~ 16% of all mtDNA
mutations in adults.3 They are primarily sporadic events
with a minimum prevalence of 1.5/100 000,3 although
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maternal transmission has been reported,4 and the risk of
transmission is higher than initially assumed.5
Single deletions give rise to three classical phenotypes;
Pearson disease, Kearns-Sayre syndrome (KSS), and pro-
gressive external ophthalmoplegia (PEO). Pearson disease
is a multisystem disorder of infancy, recognized usually
by the presence of sideroblastic anemia.6 Patients who
survive infancy develop KSS. KSS has been defined as
onset of PEO before age 20, pigmentary retinopathy and
at least one of the following features; cardiac conduction
block, cerebellar ataxia, and/or cerebrospinal fluid protein
concentration> 0.1 g/L.6 PEO is characterized by ptosis
and limited eye movement, often accompanied by proxi-
mal weakness and myopathy, in addition to other non-
muscular symptoms like hearing loss, ataxia, and other
neurological symptoms.7
A replicative selection against mutations in cells that
retain the ability to divide makes the diagnosis of mtDNA
disease challenging, since it usually means that blood
sampling is considered unsuitable for identifying mtDNA
mutations. This is particularly true for mtDNA deletions,
where skeletal muscle is regarded as the tissue of choice
for diagnosis. Recent research has, however, shown that
urine sediment cells retain sufficiently high levels of
mtDNA point mutations to allow successful diagnosis of
common mutations such as the m.3243A> G mutation.8
These cells have also been used to identify single deletions
and their breakpoints,9,10 but the finding that urine
mtDNA deletions levels were more representative of levels
found in muscle in young patients raised questions
whether these cells were appropriate for diagnosing adults
with single deletions.10 There are, however, no studies
that have addressed this question systematically. Our aim
was therefore to investigate: (a) how robust urine was for
detecting single deletions in urinary epithelial cells of
adult patients, (b) if urine could be used to map and
sequence deletion breakpoints, (c) if the degree of hetero-
plasmy detected in urine was similar to that in skeletal
muscle biopsy and (d) if we could use our data to
develop a clinical algorithm for investigating patients with
PEO.
Methods
Patient samples
We investigated 11 patients from three different centres
(Norway, Finland, The Netherlands).
In nine patients (pts 1-5, 7-10) urine and muscle sam-
ples were available while in two (pts 6 and 11) only urine
samples were available. The size of the mtDNA deletion
was, however, known from diagnostic studies of muscle.
Where available, the patient‘s muscle DNA was studied in
parallel with urine DNA in all performed assays. The time
from diagnosis in muscle to time of urinary sample varied
from 0 up to 18 years.
Urine samples were collected independent of time of
day, and immediately centrifuged for 15 min at 2000 g,
the supernatant discarded and the pellet retained. The
pellet was stored at 20°C before use. A volume of 200
ul of ultra-pure water was added to the pellet, before
DNA was extracted using the QIAmp DNA Mini-kit
(Qiagen). The manufacturer‘s tissue protocol was used
for extracting DNA from muscle, and for the urine sam-
ples the manufacturer‘s protocol for body fluids was used.
Polymerase chain reactions (PCR)
Two long-range PCR reactions (L-PCR) were used to
amplify mtDNA across the major arc, generating either
an ~ 8 kb or a ~ 16 kb product in wild-type mtDNA. A
control sample from a patient with a normal muscle
biopsy was run together.
Following primers were used: 8F (8232 – 8263) 5´-
TAAAAATCTTTGAAATAGGGCCCGTATTTACC-3´ and
L8R (16496 – 16465) 5´ - CGGATACAGTTCACTT-
TAGCTACCCCCAAGTG-3´; 15F (1650-1671) 5´-AACT-
TAACTTGACCGCTCTGAG 3´ and 15R (019-001) 5´-
GGGTGATAGACCTGTGATC-3´.
The PCR products were run on a 0.7% agarose gel at
40 V for approximately 4 hours. The wells were loaded
with 5 lL PCR product and 1 lL loading dye.
Primer sequences for “walking-PCR” were L8R in com-
bination with (5855-5875) TGTAAAACGACGGCCAG-
TACCTCAATCACACTACTCC, (6863-6882) TGTAAAAC
GACGGCCAGTATTTAGCTGACTCGCCACAC or (7713-
7723) TGTAAAACGACGGCCAGTTCCTAACACTCACA
ACAAAAC.
To establish that DNA extracted from urine sediment
cells could be used to define the deletion breakpoint, we
chose two of the patients for Sanger sequencing (pt 8 and
pt 10). Standard PCR reactions encompassing the deletion
breakpoints were performed, and a total of 25 lL with
PCR-product was run on a 0.7% agarose gel. The band
was extracted and PCR-product purified using the QIA-
quick Gel Extraction Kit (Qiagen).
PCR-products were sequenced with BigDye Termina-
tor v3.1 (ThermoFisher Scientific).
Quantitative polymerase chain reaction
We quantified the level of mtDNA deletion using quanti-
tative PCR (qPCR). The mtDNA regions ND1 and ND4
were amplified together with the single-copy nuclear gene
APP. The following primer, probes and conditions were
used. MTND1: forward primer: L3485-3504: 5´-
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CCCTAAAACCCGCCACATCT-3´, reverse primer:
H3553-3532: 5´GAGCGATGGTGAGAGCTAAGGT-3´,
TaqMan MGB probe: L3506-3529: FAM-CCATCACCCT
CTACATCACCGCCC. MTND4: forward primer: L12087-
12109: 5´-CCATTCTCCTCCTATCCCTCAAC-3´, reverse
primer: H12200-12170: 5‘- CACAATCTGATGTTTTGGT-
TAAACTATATTT-3´, TaqMan MGB probe: L12111-
12138: NED-CCGACATCATTACCGGGTTTTCCTCTTG.
APP: forward primer: 5´TGTGTGCTCTCCCAGGTCT
A-3´, reverse primer: 5´CAGTTCTGGATGGTCACTG
G-3´, TaqMan MGB probe: VIC – CCCTGAACTGCAG
ATCACCAATGTGGTAG. The reactions were run in trip-
licate with DNA template of ~ 10 ng/µl.
Thermal cycle: one cycle at 95 for 20 s, 45 cycles at
95 for 3 s, and 60 for 30 s. The percentage of deletion
was obtained with the ddCT method, using healthy blood
genomic control as calibrator.11
Next-generation sequencing
Identification of deletions in next-generation sequencing
data was performed in available urine and muscle in nine
of the patients, as previously described.12 Libraries were
prepared using the 16 kb PCR products and the Nextera
DNA Flex Library Prep kit (Illumina), and samples were
sequenced (2x150 bp) using the Illumina Nextseq 500
instrument. Raw sequencing reads were trimmed using
Trimmomatic v0.3913 with options ILLUMINACLIP:illu-
mina.fa:2:30:10 LEADING:3 TRAILING:3 SLIDINGWIN-
DOW:4:15 MINLEN:36 and mapped against the complete
human genome hg19 using bwa v0.7.1514 with default
parameters. After removal of duplicates with SAMtools
v1.915, single-nucleotide variants (SNVs) in mtDNA were
identified and filtered for each individual sample using
Genome Analysis Toolkit v3.816 (indels were discarded
and SNVs restricted to a quality score normalized by an
allele depth of at least 2 and a maximum Fisher strand
bias of 60). A new hg19 reference containing the alternate
individual mtDNA SNVs was generated for each sample
and reads were realigned with bwa. Reads with mapping
quality below 30 and/or unmapped were filtered out
using SAM tools. In order to identify deletions, align-
ments were analysed by Pindel v0.2.517 with options –x 5
and –A 30. Only deletions identified between MT:1,000-
15,000 were kept for downstream analyses. To further
reduce the false positive rate, split reads identified by Pin-
del as evidence for deletions were filtered based on a set
of stringent criteria that had to be fulfilled by both the
split read and its paired read: (1) median sequencing
quality above 36, (2) no mismatches with the mtDNA
sample-specific reference, (3) mapping quality above 0,
(4) aligned to the mtDNA chromosome with correct
paired-end orientation.
Statistical analyses
The data were processed using SPSS v25 (IBM). A P-
value < 0.05 was considered statistically significant.
Ethics
The study was approved by the Norwegian Regional
Committee for Medical and Health Research Ethics (No:
2019/481), and written consent was obtained from all
patients.
Results
Detection of single mtDNA deletions in
urine sediment cell DNA
The demographic and clinical data of the patients are
summarized in Table 1. We detected a single deletion in
urine samples from 9 of 11 patients (82%), either in 8 kb
L-PCR (Fig. 1A) and/or 16 kb L-PCR (Fig. 1B). In the
remaining two patients, the band was either very weak
(pt 2), or undetectable (pt 5). Overloading the gel did
not help with visualization.
In six of the patients (pts 3, 4, 7-10) the deletion was
detected in both 8 kb and 16 kb L-PCR. In three patients
(pts 1, 6, 11), the deletion was only detectable on the
16 kb gel, indicating that these deletions most probably
encompassed one of the 8 kb PCR primer sites. To con-
firm this, we used a process termed “walking”-PCR, in
which PCR primers are chosen to amplify regions adja-
cent to each of the original primers. Using this, we identi-
fied large deletions, each over 7 kb, in all three cases.
Heteroplasmy levels and deletion size
Mean heteroplasmy level in urine was 38%  26 (range 8
- 84%), and 57%  28 (range 12 – 94%) in muscle. The
level was generally lower in urinary sediment cells, but we
were able to define a correlation between muscle and
urine levels within our cohort (R = 0.714, P = 0.031
(Pearson correlation)) (Fig. 1C). This observation must
be interpreted with caution, however, since the finding is
based on nine patients only.
Sequencing
In the two patients (pts 8 &10) in whom we performed
Sanger sequencing; both had the common 4977 bp dele-
tion. Pt 8 had deletion junction 8469: 13447. Pt 10 had
deletion junction 8482: 13459, flanked with the 13 bp
direct repeat ACCTCCCTCACCA; a known hotspot for
deletion.
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Next-generation sequencing
All deletions detected using L-PCR in both muscle and
urine were also detected in both muscle and urine using
NGS (Table 1). However, we found that NGS generated
evidence of additional deletions of varying read depth
that were not found by L-PCR.
Discussion
The first aim of this study was to evaluate if urinary sedi-
ment cells offered a robust alternative to muscle biopsy
for the diagnosis of single mtDNA deletions in adults.
Our multicentre study shows that single deletions are
detectable in urine in over 80% of the cases who had a
clinical syndrome known to be caused by deletion, and in
whom deletion was present in skeletal muscle.
We failed to detect deletions in two patients. Since we
wanted to evaluate the efficacy of L-PCR in the clinical
setting, we did not use prior knowledge of deletion size
in the skeletal muscle to generate shorter amplicons. The
only common feature shared by these two individuals was
deletion size; they had the smallest deletions in the
cohort. Since their deletions were robustly detectable in
skeletal muscle, one explanation for our failure to detect
them in urinary cells is low heteroplasmy level. This,
however, was not the case (Table 1). Skeletal muscle
heteroplasmy levels in these two patients were not the
lowest in the group (pt 2 = 49%, pt 5 = 56%; range 12–
94%). Moreover, failure to detect small deletions would
contradict previous studies that showed an inverse corre-
lation between skeletal muscle heteroplasmy and deletion
size 7,18,19.
Our second aim was to investigate whether hetero-
plasmy level in a patient´s urine was similar to that in
skeletal muscle. We determined heteroplasmy level using
qPCR. As clinical severity and prognosis in patients with
mtDNA disorders are usually related to mutation load,
the level of heteroplasmy is of clinical interest.20 As in
previous studies,10 we found interpreting the level and
impact of heteroplasmy in urinary cells problematical.
Furthermore, four of the urine samples were taken at a
later time point than the muscle biopsy and we know that
this can affect the degree of heteroplasmy.21 Interestingly,
in contrast with muscle, urinary epithelial cells are mitotic
and thus capable of eliminating cells with comprised
energy metabolism levels due to mutated mtDNA. That
they retain mtDNA deletions at all is an interesting phe-
nomenon, and our results suggest that they do this to
levels that reflect what is found in postmitotic skeletal
muscle.
Whether heteroplasmy levels, the deletion breakpoint
and size are of clinical, predictive importance in patientsTa
b
le
1
.
D
et
ai
ls
o
f
p
h
en
o
ty
p
e,
d
el
et
io
n
si
ze
,
an
d
h
et
er
o
p
la
sm
y
le
ve
l
in
ad
u
lt
p
at
ie
n
ts
in
ve
st
ig
at
ed
in
th
is
st
u
d
y.
D
el
et
io
n
si
ze
in
g
el
an
d
N
G
S
is
b
as
ed
o
n
b
o
th
u
ri
n
e
an
d
m
u
sc
le
w
h
en
av
ai
la
b
le
Pa
ti
en
t
G
en
d
er
A
g
e
Ph
en
o
ty
p
e
D
et
ec
ta
b
le
u
ri
n
e
A
va
ila
b
le
m
u
sc
le
st
u
d
ie
d
in
p
ar
al
le
l
D
el
et
io
n
si
ze
g
el
D
el
et
io
n
si
ze
N
G
S
H
et
er
o
p
la
sm
y
u
ri
n
e
H
et
er
o
p
la
sm
y
m
u
sc
le
D
H
et
er
o
p
la
sm
y
Ti
m
e
(y
ea
rs
)
fr
o
m
m
u
sc
le
sa
m
p
lin
g
to
u
ri
n
ar
y
sa
m
p
le
1
F
4
3
PE
O
Y
es
Y
es
~
7
1
4
0
b
p
7
1
5
6
b
p
8
4
%
8
7
%
3
%
0
2
F
5
7
PE
O
N
o
Y
es
~
4
0
0
0
b
p
*
4
4
0
7
b
p
3
3
%
4
9
%
1
6
%
0
3
F
5
4
PE
O
Y
es
Y
es
~
5
-6
0
0
0
b
p
N
o
t
p
er
fo
rm
ed
8
%
3
9
%
3
1
%
0
4
F
1
7
PE
O
Y
es
Y
es
~
5
5
0
0
b
p
5
8
0
0
b
p
4
5
%
7
4
%
2
9
%
0
5
M
5
4
PE
O
N
o
Y
es
~
4
5
0
0
b
p
*
4
8
5
1
b
p
*
2
6
%
5
6
%
3
0
%
1
3
6
F
5
9
PE
O
Y
es
N
o
~
7
3
9
0
b
p
7
3
8
6
b
p
N
o
t
p
er
fo
rm
ed
N
o
t
av
ai
la
b
le
N
o
t
av
ai
la
b
le
1
8
7
F
5
6
PE
O
Y
es
Y
es
~
4
5
0
0
b
p
4
9
7
7
b
p
2
0
%
7
5
%
5
5
%
0
8
F
3
0
PE
O
Y
es
Y
es
~
4
5
0
0
b
p
4
9
7
7
b
p
1
8
%
1
2
%
6
%
1
0
9
F
2
4
PE
O
Y
es
Y
es
~
4
5
0
0
b
p
N
o
t
p
er
fo
rm
ed
7
4
%
9
4
%
2
0
%
0
1
0
M
3
2
PE
O
Y
es
Y
es
~
4
5
0
0
b
p
4
9
7
7
b
p
2
8
%
3
6
%
8
%
1
1
1
F
2
2
PE
O
Y
es
N
o
~
8
1
4
0
b
p
8
2
8
4
b
p
N
o
t
p
er
fo
rm
ed
1
2
%
N
o
t
av
ai
la
b
le
0
Th
e
si
ze
m
ar
ke
d
w
it
h
as
te
ri
x
(*
)
in
d
ic
at
es
th
at
it
is
n
o
t
d
et
ec
ta
b
le
in
u
ri
n
e,
an
d
is
th
er
ef
o
re
b
as
ed
o
n
m
u
sc
le
fi
n
d
in
g
s.
F,
fe
m
al
e;
M
,
m
al
e;
N
G
S,
n
ex
t-
g
en
er
at
io
n
se
q
u
en
ci
n
g
;
PE
O
,
p
ro
g
re
ss
iv
e
ex
te
rn
al
o
p
h
th
al
m
o
p
le
g
ia
.
ª 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association 1321
K. N. Varhaug et al. Using Urine to Diagnose mtDNA Deletions
1322 ª 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
Using Urine to Diagnose mtDNA Deletions K. N. Varhaug et al.
Figure 1. Long-range PCR analysis in patients 1-11 with single deletions in urinary sediment cells (u) and skeletal muscle (m) and control patient
(c). The wild type amplicon is 8kb in Figure (A), and 16kb in Figure (B), and marked with an arrow. A 10 kb DNA ladder is shown to the left of
each run, and vertical lines define separate experiments. In patient 6 and 11 only urinary samples were available. Due to technical problems with
patient 3 muscle, we ran the urine sample alone, and used information concerning the deletion size obtained from the diagnostic assay. (C)
shows a scatterplot illustrating the correlation between percent mutant mtDNA in muscle (x-axis) and percent mutant mtDNA in urine (y-axis)
within the same individual. Heteroplasmy levels were determined using qPCR as described under methods.
Table 2. An overview over the diversity in previous studies on single deletions
Reference Correlations Correlations not found
Zeviani et al.23 No relationship between size and site of deletion and
biochemistry or disease severity.
Holt et al.24 No correlation between heteroplasmy and clinical or
biochemical severity
No correlation between deletions site and phenotype
Aure et al.22 More severe phenotype was associated with age of onset and
the presence and proportion of deletion in blood associated
with more severe phenotype (same nonsignificant
trend was found in urine).
No correlation between phenotype and:
- Deletion size,
- Site of deletion
- Heteroplasmy
Yamashita
et al.25
Deletion size correlated with:
- Age at onset (inverse)
- Phenotype (longer deletions in KSS)
Number of deleted tRNAs correlated with:
- Age at onset (inverse)
- Phenotype (more in KSS)
Correlation between site of deletion and age of onset
No correlation between heteroplasmy and:
- Age of onset
- Phenotype
Lopez-Gallardo
et al.19
Heteroplasmy correlated with:
- Age of onset (inverse)
- Deletion size (inverse) (only in CPEO patients)
Inverse correlation between deletion size and age of onset
Correlation between site of deletion and phenotype:
- Deletion involving the Mt-CYB gene correlated with
KSS phenotype
Grady et al.18 Heteroplasmy correlates with:
- Deletion size (inverse)
- Phenotype
- Age of onset
- COX-deficient fibre densityDisease burden and progression
is predicted by:
- Heteroplasmy
- Deletion size
- Site of deletionDeletion size correlates with:
- Location of deletion
- Age of onset
Mancuso
et al.7
Inverse correlation between heteroplasmy and:
- Deletion size
- Age at onset
No correlation between phenotype and:
- Heteroplasmy
- Deletion size
Age not related to deletion size
Broomfield
et al. 9
Childhood-onset cohort.
Weak correlation between heteroplasmy and age at onset
No correlation between age of onset and deletion
size or site of deletion
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with single deletions remains unclear. Various studies
have shown contradictory findings, and we have summa-
rized these in Table 2. Some studies have suggested that
age of onset is the most important factor.22 More
recently, Grady and colleagues reanalysed previously pub-
lished data and found that there was indeed a predictive
value of heteroplasmy, size, and site of deletion on disease
burden and progression.18 Regardless of the debate con-
cerning prognostic impact of estimating deletion size, site,
and heteroplasmy level, we show that this information is
readily available in urine.
Both L-PCR and NGS detected mtDNA deletions in
DNA extracted from urine, but we found that NGS
generated evidence of additional deletions of varying read
depth that were not found by L-PCR. Since we used the
same 16 kb amplicon used for L-PCR, the noisier signal
seen with NGS is possibly related to PCR amplification
and may disappear when run on native DNA. The pur-
pose of our study was not to perform a head-to-head
comparison of these two methods, but to show that urine
was a suitable tissue for diagnosis. Currently, we believe
that L-PCR is robust and straightforward enough for
diagnostic purposes, however, future studies may well
alter this conclusion, particularly if improvements in NGS
techniques make it possible to sequence without prior
amplification.
Figure 2. Proposed diagnostic algorithm in patients with progressive external ophthalmoplegia.
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Our results suggest that urinary sediment cells are a
viable alternative to muscle biopsy for the diagnosis of sin-
gle mtDNA deletion disorder, even though we may miss
the structural and pathological information provided by a
muscle biopsy. Furthermore, although our study focused
on adults with PEO, there is no reason to believe that
diagnostic efficiency will be any less in children with KSS
or Pearson syndrome. Our results show that urine pro-
vides evidence not only of the presence of a mtDNA dele-
tion, but also permits the identification of breakpoints and
the assessment of heteroplasmy. We would therefore rec-
ommend the following algorithm (Fig. 2): urine should be
screened for single mtDNA deletions in patients with phe-
notypes known to be associated with this genetic defect.
Muscle biopsy should be reserved for patients having high
clinical suspicion but no detectable deletion in urine. We
believe that this approach will reduce the need for muscle
biopsy while maintaining diagnostic sensitivity.
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